|
WINNIPEG, Manitoba – September 3, 2010 - Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, is pleased to announce that it has completed the acquisition from PreMD Inc. of all assets relating to the PREVU* Skin Cholesterol Test. PREVU* is a simple, non-invasive, inexpensive test that addresses the major worldwide market of cardiovascular risk assessment. PREVU* has been cleared for sale in the US by the FDA (Food and Drug Administration). It has also received regulatory clearance for sale in Canada and Europe and was successfully test marketed in the US and Canada.
Read More
|
|
Possible Proceeds to Company of Up to $1,020,000
WINNIPEG, Manitoba – August 17, 2010 - Miraculins Inc. (TSX-V:MOM) (the “Company”), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, announces that it will be issuing notice of accelerated expiry to the holders (the “Warrantholders”) of share purchase warrants of the Company (the "Warrants"), which were issued pursuant to a private placement that closed on April 1, 2010.
Read More
|
|
WINNIPEG, Manitoba – August 11, 2010 – Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, is pleased to announce the launch of its PSP94 Immunoassay for Urine Specimens, a research use only (RUO) tool utilizing enzyme linked immunosorbent assay (ELISA) for the detection of PSP94 in urine. The Company is also pleased to announce the signing of a one-year non-exclusive distribution agreement with GenWay Biotech for the world-wide sales and marketing of the immunoassay.
Read More
|
|
Company Set to Aggressively Market Test Worldwide With Emphasis on US, Canada and Europe
WINNIPEG, Manitoba – August 5, 2010 - Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs is pleased to announce that it has executed a definitive agreement to acquire from PreMD Inc. all relevant assets, including intellectual property, licenses and regulatory approvals, inventories, data and marketing materials required to commercialize the PREVU* Skin Cholesterol Test.
Read More
|
|
WINNIPEG, Manitoba – July 13, 2010 – Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, is pleased to announce today that the United States Patent and Trademark Office has issued US Patent 7,754,495 entitled “Methods for Early Diagnosing of an Increased Risk of Preeclampsia”. The issued patent is a valuable addition to Miraculins’ portfolio of issued and pending patents protecting markers in its preeclampsia program, including Endoglin, the lead marker in the program. Miraculins’ preeclampsia program is being advanced in partnership with the Biosite division of Inverness Medical Innovations (NYSE:IMA).
Read More
|
|
|